|
|
|
| home > white papers > Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring - Dycem |
|
|
 WHITE PAPERS |
|
Dycem
|
|
Time lapse photography to demonstrate the potential antimicrobial abilities of Dycem contamination control flooring
|
|
A defined volume of bioluminescent reporter bacteria was deposited onto 20 mm x 20 mm coupons of Dycem flooring, vinyl tile and ITW Alma tacky mat. Through monitoring of bacterial bioluminescence, metabolic inhibition was observed on all three surfaces however the effect occurred more rapidly on Dycem flooring than on vinyl or ITW Alma. Recovery counts after three hours of exposure to the floor surfaces showed between a 65% and 100% decrease in the number of viable organisms recovered from Dycem flooring compared to controls. On vinyl and ITW Alma flooring, there were slight increases in the number of viable survivors recovered compared to controls. Dycem flooring inhibited the metabolic activity and reduced the number of viable survivors recovered of Salmonella enterica Serovar Typhimurium DT104 pGLITE. It remains unclear as to whether this effect is attributable to the impregnated biocide or rapid drying of the inoculum on this surface.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed Using Nouscom’s Proprietary Viral Vector Platform
BASEL, Switzerland – 17th May 2022 - Nouscom, a clinical stage
immuno-oncology company developing both off-the-shelf and personalized
cancer neoantigen immunotherapies, today announced that Janssen Research
& Development, LLC (Janssen) received U.S. Food and Drug
Administration (FDA) clearance for its Investigational New Drug (IND)
candidate VAC85135, an off-the-shelf, viral vector-based cancer vaccine
for an oncologic indication. VAC85135 has been exclusively licensed to
Janssen.
More info >> |
|
 |
White Papers |
 |
|
Igb Tamper Evident Folding Box
IGB
The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >> |
|
|
|
